Combretastatin A-4: OXGN began Phase I testing of its agent in the U.S., with a U.K. trial also beginning, and a third Phase I trial planned for the U.S. later

Oxigene Inc. (OXGN), Boston, Mass. Product: Combretastatin A-4 prodrug form of an angiogenesis inhibitor Indication: Treat solid tumors Status: OXGN began Phase I testing of its agent in the U.S., wit...